Sugi Predict

Sugi Predict / Compounds / SCHEMBL11786351

SCHEMBL11786351

SCHEMBL11786351

Cc1cc(-c2ccncc2)on1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.51
▸ CYP19A1 P11511 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ CSF1R P07333 1/20 0.47
▸ MAPT P10636 6/20 0.45
▸ TP53 P04637 5/20 0.45
▸ NPC1 O15118 6/20 0.43
▸ RAB9A P51151 6/20 0.43
▸ GAA P10253 2/20 0.43
▸ S1PR1 P21453 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354607 0.81 RAB9A (0.61) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
SCHEMBL2270503 0.81 NPC1 (0.59) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
SCHEMBL24307626 0.79 NPC1 (0.58) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
Ammonia Solution, Strong SCHEMBL28862474 0.79 NPC1 (0.58) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
Hydrochloric Acid SCHEMBL10941094 0.79 CYP1A2 (0.47) CYP1A2CYP19A1CYP2C9CYP2C19MAPT
SCHEMBL1672 0.78 PTPN1 (0.56) CYP1A2CYP19A1CYP2C9CYP2C19MAPT
SCHEMBL13514282 0.78 CYP1A2 (0.54) CYP1A2CYP19A1CYP2C9CYP2C19MAPT
SCHEMBL16373702 0.78 ALDH1A1 (0.58) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
SCHEMBL7904001 0.78 MAPT (0.64) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R
SCHEMBL2272084 0.78 CYP1A2 (0.54) CYP1A2CYP19A1CYP2C9CYP2C19CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 — — EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 — — US disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 — — US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 — — EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 — — US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 — — US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 — — US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 — — US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 — — US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 — — US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 — — US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 — — US disclosed
US-20140113931-A1 SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-04-24 — — US disclosed
US-3985754-A Para-fluorobenzoylpropyl-N-heterocyclic substituted quaternary salts AMERICAN CYANAMID COMPANY (US) 1976-10-12 — — US disclosed
US-3966748-A NEUROLEPTIC, ANALGESIC AMERICAN CYANAMID COMPANY (US) 1976-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP1A2 1759/4885CYP19A1 1903/4885CYP2C9 1572/4885
US-20140113931-A1 SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS SYK, LCK, BTK CYP1A2 3933/4885CYP19A1 3963/4885CYP2C9 3041/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP1A2 2353/4885CYP19A1 2723/4885CYP2C9 1638/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP1A2 1759/4885CYP19A1 1903/4885CYP2C9 1572/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP1A2 2067/4885CYP19A1 2660/4885CYP2C9 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.